Latest market price
78.63
-2.21-2.74%
OverviewShort InterestFilings
IRONQT61Disc Medicine, Inc.·NASDAQ
78.63-2.74%
News
Down 2.7% — Disc Medicine to Participate in Upcoming Investor Conferences (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
DYN+1.95%$17.02IDYA-1.85%$31.37DNLI-0.58%$18.83TLX+0.24%$9.12ELVN+0.34%$44.40NRIX-3.71%$25.81CELC-2.23%$67.59BEAM-4.02%$26.14
Snapshot
Index—P/E—EPS (ttm)-6.60Insider Own23.48%Shs Outstand38.39MPerf Week8.50%
Market Cap3.10BForward P/E—EPS next Y-6.63Insider Trans-3.08%Shs Float28.15MPerf Month27.09%
Enterprise Value2.45BPEG—EPS next Q-1.63Short Float26.49%Perf Quarter5.94%
Income-247.00MP/S—EPS this Y—Short Ratio15.13Perf Half Y20.82%
Sales0.00P/B4.82EPS next Y—ROA-33.45%Short Interest7.46MPerf YTD1.80%
Book/sh16.77P/C4.32EPS next 5Y—ROE-37.17%52W High99.50 -20.98%Perf Year-4.89%
Cash/sh18.70P/FCF—EPS past 3/5Y—ROIC-38.19%52W Low40.00 96.57%Perf 3Y86.91%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility4.82% 5.53%Perf 5Y129.66%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)4.11Perf 10Y—
Dividend Ex-Date—Quick Ratio24.14Sales Y/Y TTM—Profit Margin0.00%RSI (14)64.80Recom1.91
Dividend Gr. 3/5Y—Current Ratio24.14EPS Q/Q2.53%SMA2016.85%Beta0.94Target Price127.14
Payout0.00%Debt/Eq0.09Sales Q/Q—SMA5013.28%Rel Volume0.83Prev Close80.84
Employees165LT Debt/Eq0.09EarningsNov 05SMA20014.37%Avg Volume822.69KPrice78.63
IPO DateAug 12, 2020Option/ShortYes / YesEPS/Sales Surpr.10.08% —Net Debt/EBITDA—Volume684,972Change-2.74%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-21-26ReiteratedJefferies$128 → $149
Oct-20-26ReiteratedWells FargoOverweight$86 → $124
Oct-20-26ReiteratedMorgan StanleyOverweight$90 → $92
Oct-19-26ReiteratedCantor FitzgeraldOverweight$125 → $170
Oct-19-26ReiteratedBMO CapitalOutperform$100 → $120
Sep-16-26ReiteratedWells FargoOverweight$75 → $86
Sep-10-26ReiteratedH.C. WainwrightBuy$70 → $120
Sep-10-26ReiteratedJefferies$89 → $128
Aug-17-26ReiteratedMorgan StanleyOverweight$85 → $90
May-14-26ReiteratedMorgan StanleyOverweight$75 → $80
Latest News· Times ET
Today
Today08:30AM
Disc Medicine to Participate in Upcoming Investor Conferencesglobenewswire.com
Oct-21-26
Oct-21-2611:30PM
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal StudyYahoo
Oct-20-26
Oct-20-2608:52PM
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stockglobenewswire.com
08:59AM
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayYahoo
Oct-19-26
Oct-19-2604:01PM
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrantsglobenewswire.com
03:53PM
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcriptseekingalpha.com
12:33PM
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Studybenzinga.com
12:23PM
Disc Medicine stock soars: take profit or buy into strength?invezz.com
12:14PM
Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatmentgurufocus.com
12:02PM
Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmissionmarketbeat.com
11:28AM
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopesbarrons.com
11:08AM
Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpointsproactiveinvestors.com
08:06AM
Disc Medicine's rare disease drug succeeds in late-stage trialreuters.com
07:00AM
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)globenewswire.com
Oct-18-26
Oct-18-2605:00PM
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)globenewswire.com
Company

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
0000———
Cost of Goods Sold Incl. D&A
0000———
Gross Profit
0000———
Selling, General and Administrative Excl. Other80653322———
Research and Development1891719769———
Other Operating Expense
1000———
Operating Income-270-236-130-91———
Interest Expense4410———
Unusual Expense
———————
Non-Operating Income (Expense)27282115———
Net Income Before Taxes-244-212-109-76———
Income Taxes
0000———
Consolidated Net Income-247-212-109-76———
Net Income From Continuing Operations-247-212-109-76———
Net Income-247-212-109-76———
EPS (Recurring)-6.60-6.01-3.96-3.42———
EPS (Basic, Before Extraordinaries)-6.60-6.01-3.96-3.42———
EPS (Diluted)-6.60-6.01-3.96-3.42———
EBITDA-241-208-108-76———
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding39352822———
Market Capitalization3,0662,7791,7751,271———
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$99.87$87.40$74.92$62.45$49.98● Close Price0.00M5.46M10.92M16.38M21.84MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bitterman KevinDirectorOct 21 '26Sale80.2325,5192,047,38912,991Oct 21
Bitterman KevinDirectorOct 20 '26Sale79.955,312424,69513,257Oct 21
Bitterman KevinDirectorOct 19 '26Sale79.9710,994879,19113,312Oct 21
Quisel John DChief Executive OfficerSep 15 '26Option Exercise1.0136,00036,360262,064Sep 16
Bitterman KevinDirectorSep 11 '26Option Exercise45.0727,1361,223,14427,136Sep 15
Bitterman KevinDirectorSep 11 '26Sale70.1127,1361,902,5050Sep 15
Bitterman KevinDirectorSep 04 '26Sale79.961,689135,05313,427Sep 09
Bitterman KevinDirectorSep 03 '26Sale79.985,203416,13613,445Sep 03
Bitterman KevinDirectorSep 02 '26Sale80.1749,1643,941,49513,499Sep 03
Bitterman KevinDirectorSep 01 '26Sale79.9512910,31414,012Sep 03
Yu Jonathan Yen-WenChief Operating OfficerAug 25 '26Sale83.128,796731,09254,324Aug 26
Yu Jonathan Yen-WenChief Operating OfficerAug 25 '26Option Exercise13.508,796118,74663,120Aug 26
Yu Jonathan Yen-WenChief Operating OfficerAug 24 '26Sale82.5330024,76054,324Aug 26
Yu Jonathan Yen-WenChief Operating OfficerAug 24 '26Option Exercise13.503004,05054,624Aug 26
Quisel John DChief Executive OfficerAug 17 '26Option Exercise13.5033,000445,500259,064Aug 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.